Mesoblast Ltd. (MESO)
14.87
+0.46
(+3.19%)
USD |
NASDAQ |
Sep 17, 16:00
14.58
-0.29
(-1.95%)
After-Hours: 20:00
Mesoblast Enterprise Value : 1.973B for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 1.973B |
| September 16, 2026 | 1.914B |
| September 15, 2026 | 1.956B |
| September 14, 2026 | 1.993B |
| September 11, 2026 | 2.052B |
| September 10, 2026 | 2.055B |
| September 09, 2026 | 2.138B |
| September 08, 2026 | 2.170B |
| September 04, 2026 | 2.291B |
| September 03, 2026 | 2.268B |
| September 02, 2026 | 2.287B |
| September 01, 2026 | 2.185B |
| August 31, 2026 | 2.218B |
| August 28, 2026 | 2.307B |
| August 27, 2026 | 2.403B |
| August 26, 2026 | 2.229B |
| August 25, 2026 | 2.274B |
| August 24, 2026 | 2.203B |
| August 21, 2026 | 2.250B |
| August 20, 2026 | 2.305B |
| August 19, 2026 | 2.266B |
| August 18, 2026 | 2.207B |
| August 17, 2026 | 2.252B |
| August 14, 2026 | 2.067B |
| August 13, 2026 | 2.183B |
| Date | Value |
|---|---|
| August 12, 2026 | 2.221B |
| August 11, 2026 | 2.239B |
| August 10, 2026 | 2.208B |
| August 07, 2026 | 2.112B |
| August 06, 2026 | 2.071B |
| August 05, 2026 | 1.985B |
| August 04, 2026 | 1.964B |
| August 03, 2026 | 1.921B |
| July 31, 2026 | 1.883B |
| July 30, 2026 | 1.932B |
| July 29, 2026 | 1.877B |
| July 28, 2026 | 1.919B |
| July 27, 2026 | 1.933B |
| July 24, 2026 | 2.030B |
| July 23, 2026 | 2.130B |
| July 22, 2026 | 2.159B |
| July 21, 2026 | 2.174B |
| July 20, 2026 | 2.202B |
| July 17, 2026 | 2.291B |
| July 16, 2026 | 2.361B |
| July 15, 2026 | 2.410B |
| July 14, 2026 | 2.216B |
| July 13, 2026 | 2.148B |
| July 10, 2026 | 2.047B |
| July 09, 2026 | 1.968B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 1.681M |
| Actinogen Medical Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -3.00% |
| Normalized Earnings Yield | -3.481 |